Tracking Epstein-Barr virus reactivation in adults 18–29
A Multi-center, Prospective, Longitudinal Cohort Study to Collect Immunological and Clinical Data on Epstein-Barr Virus (EBV) Reactivation in EBV Seropositive Male and Female Adults Aged 18 to 29 Years
This study will follow EBV-positive adults aged 18 to 29 to see how and when the virus reactivates and to collect immune and symptom information over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 29 Years |
| Sex | All |
| Sponsor | Sanofi Industry-sponsored |
| Locations | 1 site (Gold Coast) |
| Trial ID | NCT07536048 on ClinicalTrials.gov |
What this trial studies
This is a multi-center, prospective, longitudinal cohort of about 100 EBV-seropositive adults aged 18–29 in Australia followed for either 6 or 12 months. Participants receive no study treatments and undergo periodic clinical and immunological sampling and monitoring to document episodes of viral reactivation and related symptoms. Data collected will include clinical observations and laboratory immune markers to characterize timing and patterns of reactivation. The aim is to build a detailed longitudinal dataset to inform understanding of EBV behavior in young adults.
Who should consider this trial
Good fit: Healthy adults aged 18 to 29 who are EBV-seropositive, able to provide informed consent, and able to remain in the study area for the 6- or 12-month follow-up are ideal candidates.
Not a fit: People who are EBV-seronegative, outside the 18–29 age range, have medical conditions affecting study assessments, or plan to leave the area before study end are unlikely to benefit or be eligible.
Why it matters
Potential benefit: If successful, the study could clarify when EBV reactivation occurs and identify immune signals linked to reactivation, which may inform future prevention or vaccine strategies.
How similar studies have performed: Prior longitudinal observational studies of EBV have yielded useful insights into reactivation patterns and immune responses, but consistent predictive markers in young adults remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 to 29 years on the day of inclusion * Participants who are healthy as determined by medical evaluation including medical history and physical examination * Participants who are EBV seropositive based on serology testing Exclusion Criteria: Any condition which in the opinion of the investigator might interfere with the evaluation of the study objectives, including planning to leave the area of the study before the end of study period The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Where this trial is running
Gold Coast
- Griffith - University Clinical Trial UnitSite Number : 0360001 — Gold Coast, Australia (Recruiting)
Study contacts
- Study coordinator: Trial Transparency email recommended (Toll free for US & Canada)
- Email: contact-us@sanofi.com
- Phone: 800-633-1610
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.